2 Information about lutetium (177Lu) oxodotreotide

2 Information about lutetium (177Lu) oxodotreotide

Information about lutetium (177Lu) oxodotreotide

Marketing authorisation indication

Lutetium (177Lu) oxodotreotide (Lutathera, AAA, referred to as lutetium) is indicated for 'unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP NETs) in adults'.

Dosage in the marketing authorisation

Lutetium is administered as an intravenous infusion. A single cycle consists of 4 infusions of 7.4 gigabecquerels (GBq). The recommended interval between infusions is 8 weeks.


£71,500.00 for 4 administrations of 7.4 GBq (excluding VAT; company submission).

The company has a commercial arrangement. This makes lutetium available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)